Abzena Share News (ABZA)

Abzena Forms Venture With US Research Institute For Immunotherapies

Abzena Sees Widened Annual Loss On Investment, Exceptional Costs

Imperial Innovations Portfolio Value Rises, First Half Loss Narrows

Abzena Expects Strong Momentum To Continue For Foreseeable Future

Abzena Inks "Significant" Licensing Deal With US Biotech Firm

Abzena Says Antitope Consortium Gets EUR1.9 Million European Grant

Abzena Says Partner Gilead Opts To Stop Phase II Study Of Simtuzumab

Abzena To Buy Chemistry Research Solution, Raise GBP20 Million (ALLISS)

CORRECT: Abzena Notes Acquisition Of Customer By Pharma Major Roche

Abzena highlights Roche's acquisition of Adheron Therapeutics

(ShareCast News) - Life sciences company Abzena announced that Roche has acquired Adheron Therapeutics, which is a privately-held biotechnology company developing the SPD051 product that disrupts cell adhesion using Abzena's Composite Human Antibody technology. Adheron has completed a Phase I study

Abzena Notes Acquisition Of Affiliate By Major Pharma Company Roche

Abzena Expects "Significantly Higher" Services Revenue For Half Year

CORRECT: AGM, EGM Calendar - Week Ahead

AGM, EGM Calendar - Week Ahead

Abzena completes PacificGMP deal

(ShareCast News) - Life sciences group Abzena has completed the acquisition of biopharmaceutical development and manufacturing company PacificGMP for $7.7m in cash and stock. In a statement released on Monday, the company said the acquisition will be financed by existing cash resources and by the is